Dr. Fedorak and Dr. Wang collaborated with the metabolomics group at the University of Alberta in Canada to develop the test, which is currently in beta testing.
The test is designed to detect both colorectal cancer and precancerous polyps. PolypDx has been found to have a sensitivity of 71 percent and specificity of 61 percent.
More Articles on Gastroenterology:
Creating an IBD Collaborative System of Care: 6 Key Elements From Dr. Vera Denmark
Dr. M. Babitha Reddy to Practice at New Mercy Family Medicine Clinic
5 Opportunities for GI Centers to Overcome Healthcare Reform Challenges
